Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Scheithauer

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Therapeutic Advances in Medical Oncology|July 31, 2019
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acidMarkus Kieler, Matthias Unseld, Daniela Bianconi, et al.
BMC Cancer|April 29, 2008
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastasesBirgit Gruenberger, Werner Scheithauer, Robert Punzengruber, et al.
Anticancer Research|December 29, 2010
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposesAndre Farkouh, Dagmar Ettlinger, Johannes Schueller, et al.
Wiener Klinische Wochenschrift|April 24, 2003
[Drug therapy of colorectal carcinoma]Herbert Ulrich-Pur, Barbara Jech, Werner Scheithauer, et al.
Oncology Research and Treatment|March 12, 2014
Clinical benefit response in pancreatic cancer trials revisitedJürg Bernhard, Daniel Dietrich, Bengt Glimelius, et al.
Oncology|July 25, 2009
Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancerLaurenz Vormittag, Andreas Gleiss, Werner Scheithauer, et al.
American Journal of Surgery|February 22, 2005
Treatment and outcome of intrahepatic cholangiocellular carcinomaHarald Puhalla, Birgit Schuell, Herwig Pokorny, et al.
European Journal of Clinical Investigation|August 23, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpressionThorsten Fuereder, Judith Stift, Irene Kuehrer, et al.
ESMO Open|March 4, 2017
Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky diseaseMarkus Kieler, Werner Scheithauer, Christoph C Zielinski, et al.
Thrombosis Research|January 17, 2020
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancerFlorian Moik, Florian Posch, Ella Grilz, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Medical Oncology|July 31, 2019
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acidMarkus Kieler, Matthias Unseld, Daniela Bianconi, et al.
BMC Cancer|April 29, 2008
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastasesBirgit Gruenberger, Werner Scheithauer, Robert Punzengruber, et al.
Anticancer Research|December 29, 2010
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposesAndre Farkouh, Dagmar Ettlinger, Johannes Schueller, et al.
Wiener Klinische Wochenschrift|April 24, 2003
[Drug therapy of colorectal carcinoma]Herbert Ulrich-Pur, Barbara Jech, Werner Scheithauer, et al.
Oncology Research and Treatment|March 12, 2014
Clinical benefit response in pancreatic cancer trials revisitedJürg Bernhard, Daniel Dietrich, Bengt Glimelius, et al.
Oncology|July 25, 2009
Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancerLaurenz Vormittag, Andreas Gleiss, Werner Scheithauer, et al.
American Journal of Surgery|February 22, 2005
Treatment and outcome of intrahepatic cholangiocellular carcinomaHarald Puhalla, Birgit Schuell, Herwig Pokorny, et al.
European Journal of Clinical Investigation|August 23, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpressionThorsten Fuereder, Judith Stift, Irene Kuehrer, et al.
ESMO Open|March 4, 2017
Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky diseaseMarkus Kieler, Werner Scheithauer, Christoph C Zielinski, et al.
Thrombosis Research|January 17, 2020
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancerFlorian Moik, Florian Posch, Ella Grilz, et al.
Pageof 9